1. Analyst View 2. Research Methodology 3. Cancer Statistics by Demographics 3.1 Prevalence, Incidences and Mortality 3.2 Leading States by Incidences 3.3 Leading Cancers by Incidences 3.3.1 Male Cancer Incidences 3.3.2 Female Cancer Incidences 3.3.3 Children Cancer Incidences 4. Market Dynamics 4.1 Drivers 4.1.1 Rising Cancer Incidences 4.1.2 Ability to Reduce Healthcare Expenditure 4.1.3 Rising Awareness 4.1.4 Patient Assistance Programs 4.1.5 Government Initiatives 4.1.6 Strong Pipeline 4.1.7 Technological Advancements 4.2 Restraints 4.2.1 High Cost of Cancer Vaccines 4.2.2 Side-Effects of Cancer Vaccines 4.2.3 Vaccine Supply Shortages 4.2.4 Insurance Issues Related to Cancer Vaccination 4.3 Opportunities 4.3.1 Therapeutic Cancer Vaccines 4.3.2 Adjuvant Cancer Vaccines 5. Cancer Vaccines Market Outlook 5.1 Key Product Analysis 5.1.1 Provenge 5.1.1.1 Market Analysis 5.1.2 T-Vec/Imlygic 5.1.2.1 Market Analysis 5.1.3 HPV Vaccine 5.1.3.1 Gardasil 5.1.3.1.1 Market Analysis 5.1.3.2 Cervarix 5.1.3.2.1 Market Analysis 5.1.4 HBV Vaccines 5.1.4.1 Engerix-B & Twinrix 5.1.4.1.1 Market Analysis 5.1.4.2 Recombivax HB 5.1.4.2.1 Market Analysis 5.1.4.3 Pediarix/ Infanrix 5.1.4.3.1 Market Analysis 6. Cancer Vaccines Market by Cancer Type 7. Cancer Vaccine Market by Application 8. Potential Cancer Vaccine Candidates: An Opportunity Assessment 8.1 Prophylactic Vaccine 8.2 Therapeutic Vaccine 8.2.1 Prostate Cancer 8.2.2 Breast Cancer 8.2.3 Lung Cancer 8.2.4 Colorectal Cancer 9. US Patent Analysis 9.1 Patents by Year 9.2 Patents by Category 9.2.1 Utility Patents 9.2.2 Design Patents 9.2.3 Plant Patents 9.3 Patents by Company 9.4 Patents by Assignee Type 9.4.1 By Assignee Name 9.4.2 By Assignee State 10. Regulatory Environment 10.1 Vaccine Approval Process 10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines 10.2.1 Considerations for both Early and Late Phase Clinical Trials 10.2.1.1 Patient Population 10.2.1.2 Monitoring the Immune Response 10.2.1.3 Biomarkers as Evidence of Efficacy 10.2.1.4 Adjuvants Used to Stimulate Immune Response 10.2.1.5 Multi-antigen Vaccines 10.2.1.6 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines 10.2.1.7 Concomitant and Subsequent Therapies 10.2.2 Considerations for Early Phase Clinical Trials 10.2.2.1 Starting Dose and Dosing Schedule 10.2.2.2 Booster and Maintenance Therapy 10.2.2.3 Dose Escalation 10.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early Development 10.2.3 Considerations for Late Phase Clinical Trials 10.2.3.1 Safety Profile from Early Phase Clinical Trials 10.2.3.2 Endpoints 10.2.3.3 Statistical Issues 10.2.3.4 Control Issues 10.2.3.5 Delayed Vaccine Effect 10.2.3.6 Autologous Vaccine Trials 10.2.3.7 Accelerated Approval Regulations 11. Competitive Landscape 12. Company Profiles 12.1 Merck & Co., Inc. 12.2 GlaxoSmithKline plc. 12.3 Dendreon Pharmaceuticals LLC 12.4 Amgen Inc.

List of Tables: Table 3-1: Top 10 Cancer Incidences in Males (2018) Table 3-2: Top 10 Cancer Incidences in Females (2018) Table 3-3: Top 10 Cancer Incidences in Children (Ages 0-14), (2018) Table 4-1: Cancer Incidences (Million), 2015, 2020 & 2025 Table 8-1: Cancers with High Linkage to Virus and Bacteria Table 8-2: Prophylactic Cancer Vaccines in Clinical Trials Table 8-3: Therapeutic Cancer Vaccines in Clinical Trials Table 8-4: Prostate Cancer Therapeutic Vaccines in Clinical Trials Table 8-5: Breast Cancer Therapeutic Vaccines in Clinical Trials Table 8-6: Lung Cancer Therapeutic Vaccines in Clinical Trials Table 8-7: Colorectal Cancer Therapeutic Vaccines in Clinical Trials Table 12-1: Merck & Co., Inc. - Key Financials (Million US$), 2015-2017 Table 12-2: Merck & Co., Inc. - Product Portfolio Table 12-3: Merck & Co., Inc. - Cancer Vaccines in Pipeline Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2015-2017 Table 12-5: GlaxoSmithKline - Product Portfolio Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline Table 12-7: Dendreon Pharmaceuticals LLC - Product Portfolio Table 12-8: Amgen Inc. - Key Financials (Million US$), 2015-2017 Table 12-9: Amgen Inc. - Product Portfolio List of Figures: Figure 3-1: Cancer Incidences (Million), 2015 & 2025 Figure 3-2: Cancer Mortality (Million), 2015 & 2025 Figure 3-3: Incidences by Cancer Type (%), 2018 Figure 3-4: States with Highest Cancer Incidences, 2018 Figure 5-1: Global - Cancer Vaccine Market (Million US$), 2016-2023 Figure 5-2: US - Cancer Vaccine Market (Million US$), 2016-2023 Figure 5-3: Share of US in Global Cancer Vaccine Market (%), 2017 Figure 5-4: US - Cancer Vaccine Market by Product Type (%), 2017 Figure 5-5: US - Provenge Market (Million US$), 2013-2017 Figure 5-6: Share of US in Global Imlygic Sales (%), 2017 Figure 5-7: Global - Gardasil Market (Million US$), 2013-2017 Figure 5-8: US - Gardasil Market (Million US$), 2013-2017 Figure 5-9: Share of US in Global Gardasil Sales (%), 2017 Figure 5-10: Global - Cervarix Market (Million US$), 2013-2017 Figure 5-11: US - Cervarix Market (Million US$), 2013-2017 Figure 5-12: Share of US in Global Cervarix Sales (%), 2017 Figure 5-13: Global - Engerix-B & Twinrix Market (Million US$), 2013-2017 Figure 5-14: US - Engerix-B & Twinrix Market (Million US$), 2013-2017 Figure 5-15: Share of US in Global Engerix-B & Twinrix Sales (%), 2017 Figure 5-16: Global - Recombivax HB Market (Million US$), 2013-2017 Figure 5-17: US - Recombivax HB Market (Million US$), 2013-2017 Figure 5-18: Share of US in Global Recombivax HB Sales (%), 2017 Figure 5-19: Global - Pediarix/Infanrix Market (Million US$), 2013-2017 Figure 5-20: US - Pediarix/ Infanrix Market (Million US$), 2013-2017 Figure 5-21: Share of US in Global Pediarix/Infanrix Sales (%), 2017 Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2017 Figure 6-2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2016-2023 Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2016-2023 Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2016-2023 Figure 7-1: US - Cancer Vaccine Market by Application (%), 2017 Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2016-2023 Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2016-2023 Figure 8-1: Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2017 Figure 8-2: Prophylactic Cancer Vaccines in Clinical Trials by Phases (%), 2017 Figure 8-3: Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2017 Figure 8-4: Therapeutic Cancer Vaccines in Clinical Trials by Phases (%), 2017 Figure 8-5: Cancer Vaccines in Clinical Trials by Application (%), 2017 Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2017 Figure 12-1: Merck & Co., Inc. - Breakup of Sales by Business Segment (%), 2017 Figure 12-2: Merck & Co., Inc. - Breakup of Sales by Geography (%), 2017 Figure 12-3: GlaxoSmithKline - Breakup of Group Turnover by Business Segment (%), 2017 Figure 12-4: GlaxoSmithKline - Breakup of Group Turnover by Geography (%), 2017 Figure 12-5: Amgen Inc. - Breakup of Revenue by Geography (%), 2017